Kecellitics Biotech Company Ltd Report issue

Government Phase 2

Organization Overview

First Clinical Trial
2019
NCT04100187
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Kecellitics Biotech Company Ltd

Active Ingredients

Drugs in Phase 2 Trials (2)

cd19 car-t cells (2 trials)

cd22 car-t cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2